• 1. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles

Introduction to 6-(Pyridin-3-yl)-1H-indole (CAS No. 147621-19-0)

6-(Pyridin-3-yl)-1H-indole, identified by its Chemical Abstracts Service number CAS No. 147621-19-0, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its versatile structural framework and potential biological activities. This compound belongs to the class of indole derivatives, which are well-documented for their role in various biological processes and therapeutic applications. The presence of a pyridine moiety at the 3-position of the indole ring introduces unique electronic and steric properties, making it a valuable scaffold for drug discovery and development.

The structural combination of indole and pyridine in 6-(Pyridin-3-yl)-1H-indole creates a molecule with potential interactions across multiple biological targets. Indole derivatives are well-known for their involvement in neurotransmitter synthesis, immune modulation, and anti-inflammatory responses, while pyridine-based compounds often exhibit properties such as kinase inhibition and receptor binding. The synergistic effects of these two moieties make 6-(Pyridin-3-yl)-1H-indole a promising candidate for further exploration in medicinal chemistry.

In recent years, there has been a surge in research focused on developing novel therapeutic agents based on indole-pyridine hybrids. These compounds have shown promise in preclinical studies as modulators of various signaling pathways implicated in diseases such as cancer, neurodegenerative disorders, and infectious diseases. The structural flexibility of 6-(Pyridin-3-yl)-1H-indole allows for facile modifications at both the indole and pyridine rings, enabling the optimization of pharmacokinetic properties and target specificity.

One of the most compelling aspects of 6-(Pyridin-3-yl)-1H-indole is its potential as an anti-cancer agent. Studies have demonstrated that indole derivatives can induce apoptosis in cancer cells by modulating key cellular pathways such as the PI3K/Akt and MAPK signaling cascades. The pyridine substituent further enhances this potential by facilitating interactions with intracellular targets involved in cancer progression. Recent research has highlighted the ability of 6-(Pyridin-3-yl)-1H-indole to inhibit the growth of several cancer cell lines by disrupting microtubule formation and inducing cell cycle arrest.

Another area where 6-(Pyridin-3-yl)-1H-indole has shown promise is in the treatment of neurodegenerative diseases. The indole moiety is known to have neuroprotective properties, and studies have suggested that it can mitigate oxidative stress and inflammation associated with conditions such as Alzheimer's disease and Parkinson's disease. The pyridine component may enhance these effects by interacting with neurotransmitter receptors, thereby improving cognitive function. Preliminary findings indicate that 6-(Pyridin-3-yl)-1H-indole can attenuate neurotoxicity in models of neurodegeneration, making it a potential therapeutic candidate for these debilitating conditions.

The synthesis of 6-(Pyridin-3-yl)-1H-indole involves multi-step organic reactions that typically include condensation, cyclization, and functional group transformations. Advanced synthetic methodologies have been employed to improve yield and purity, ensuring that the final product meets pharmaceutical standards. Techniques such as palladium-catalyzed cross-coupling reactions have been particularly useful in constructing the indole-pyridine core structure efficiently.

From a pharmacological perspective, the bioavailability and metabolic stability of 6-(Pyridin-3-yl)-1H-indole are critical factors that influence its clinical efficacy. Research efforts have focused on optimizing these properties through structural modifications. For instance, introducing lipophilic groups at strategic positions can enhance membrane permeability, while polar functional groups can improve solubility in aqueous environments. These modifications aim to achieve a balance between potency and pharmacokinetic profiles, ensuring that the compound reaches its target sites effectively.

The role of computational chemistry in the study of 6-(Pyridin-3-yl)-1H-indole cannot be overstated. Molecular modeling techniques have been instrumental in predicting binding affinities, identifying potential drug-target interactions, and optimizing molecular structures for improved activity. These computational approaches complement experimental data by providing insights into the molecular mechanics of drug-receptor interactions, thereby expediting the drug discovery process.

In conclusion, 6-(Pyridin-3-yl)-1H-indole (CAS No. 147621-19-0) represents a significant advancement in medicinal chemistry due to its unique structural features and multifaceted biological activities. Its potential applications in oncology, neurology, and other therapeutic areas make it a compelling subject for further research. As our understanding of biological pathways continues to evolve, compounds like 6-(Pyridin-3-yl)-1H-indole will play an increasingly important role in developing innovative treatments for human diseases.

• 52191-68-1(Quinoline, 4-(1H-indol-3-yl)-)
• 144104-49-4(5-pyridin-3-yl-1H-indole)
• 25796-86-5(3-Phenyl-1H-pyrrolo[3,2-c]pyridine)
• 7496-93-7(2-phenylpyrrolo[2,1-a]isoquinoline)
• 7496-94-8(2-phenylpyrrolo[1,2-b]isoquinoline)
• 13637-37-1(1H,1'H-3,3'-Biindole)
• 827025-07-0(1H-Indole, 7-(4-pyridinyl)-)
• 106047-26-1(Quinoline, 3-(4-pyridinyl)-)
• 108378-92-3(1H-Indole, 4-(3-pyridinyl)-)
• 7272-84-6(3-(4-Pyridyl)indole)